Rate of discontinuation and drug survival of biologic therapies in rheumatoid arthritis: A systematic review and meta-analysis of drug registries and health care databases

Rheumatology (United Kingdom)

Volumn 55, Issue 3, 2016, Pages 523-534

  Souto, Alejandro ^a   Maneiro, José Ramón ^a   Gómez Reino, Juan J ^a,b  

^a HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^b UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

Author keywords

Biologic; Discontinuation; Drug survival; Rheumatoid arthritis

Indexed keywords

ABATACEPT; ADALIMUMAB; ANTIRHEUMATIC AGENT; BIOLOGICAL PRODUCT; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GLUCOCORTICOID; GOLIMUMAB; INFLIXIMAB; RITUXIMAB; TOCILIZUMAB; TUMOR NECROSIS FACTOR INHIBITOR;

ARTICLE; BIOLOGICAL THERAPY; DATA BASE; DISEASE DURATION; DRUG WITHDRAWAL; HEALTH CARE; HUMAN; META ANALYSIS; PREVALENCE; PRIORITY JOURNAL; REGISTER; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; SENSITIVITY ANALYSIS; SURVIVAL; SYSTEMATIC REVIEW; TREATMENT WITHDRAWAL;

EID: 84965033914     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kev374     Document Type: Article

References (132)

1. Modena V, Bianchi G, Roccatello D. Cost-effectiveness of biologic treatment for rheumatoid arthritis in clinical practice: an achievable target? Autoimmun Rev 2013;12:835-8.
2. Keystone EC, Kavanaugh AF, Sharp JT et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum 2004;50:1400-11.
3. Scott DL. Biologics-based therapy for the treatment of rheumatoid arthritis. Clin Pharmacol Ther 2012;91:30-43.
4. Singh JA, Christensen R, Wells GA et al. A network metaanalysis of randomized controlled trials of biologics for rheumatoid arthritis: a Cochrane overview. CMAJ 2009;181:787-96.
5. Aletaha D, Smolen JS. Effectiveness profiles and dose dependent retention of traditional disease modifying antirheumatic drugs for rheumatoid arthritis. An observational study. J Rheumatol 2002;29:1631-8.
6. Fries JF. Effectiveness and toxicity considerations in outcome directed therapy in rheumatoid arthritis. J Rheumatol Suppl 1996;44:102-6.
7. Pincus T, Marcum SB, Callahan LF. Longterm drug therapy for rheumatoid arthritis in seven rheumatology private practices: II. Second line drugs and prednisone. J Rheumatol 1992;19:1885-94.
8. Cush J, Kay J, Dao K. Does Rheumatoid arthritis or biologic therapy increase cancer risk? Drug Safety Q 2012;4:e1-4
9. Elkayam O, Pavelka K. Biologic registries in rheumatology:lessons learned and expectations for the future. Autoimmun Rev 2012;12:329-36.
10. Kremer JM, Gibofsky A, Greenberg JD. The role of drug and disease registries in rheumatic disease epidemiology. Curr Opin Rheumatol 2008;20:123-30.
11. Neumann PJ. Communicating and promoting comparativeeffectiveness research findings. N Engl J Med 2013;369:209-11.
12. Schneeweiss S, Seeger JD, Jackson JW, Smith SR. Methods for comparative effectiveness research/patientcentered outcomes research: from efficacy to effectiveness. J Clin Epidemiol 2013;66:S1-4.
13. Liberati A, Altman DG, Tetzlaff J et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med 2009;151:W65-94.
14. Putrik P, Ramiro S, Kvien TK et al. Inequities in access to biologic and synthetic DMARDs across 46 European countries. Ann Rheum Dis 2014;73:198-206.
15. Wells G, Shea B, O'Connell D et al. The Newcastle Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. In: Proceedings of the 3rd Symposium on Systematic Reviews: Beyond the Basics, St Catherine's College, 3-5 July 2000. Oxford, UK: Centre for Statistics in Medicine.
16. OCEBM Levels of Evidence Working Group. The Oxford Levels of Evidence 2. Oxford, UK: Oxford Centre for Evidence-Based Medicine, 2009. http://www.cebm. net/index.aspx?o=5653 (January 2015, date last accessed).
17. Gisbert JP, Marin AC, McNicholl AG, Chaparro M. Systematic review with meta-analysis: the efficacy of a second anti-TNF in patients with inflammatory bowel disease whose previous anti-TNF treatment has failed. Aliment Pharmacol Ther 2015;41:613-23.
18. Raval AD, Thakker D, Vyas A et al. Impact of metformin on clinical outcomes among men with prostate cancer: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis 2015;18:110-21.
19. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629-34.
20. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002;21:1539-58.
21. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-60.
22. Agarwal SK, Glass RJ, Shadick NA et al. Predictors of discontinuation of tumor necrosis factor inhibitors in patients with rheumatoid arthritis. J Rheumatol 2008;35:1737-44.
23. Blom M, Kievit W, Fransen J et al. The reason for discontinuation of the first tumor necrosis factor (TNF) blocking agent does not influence the effect of a second TNF blocking agent in patients with rheumatoid arthritis. J Rheumatol 2009;36:2171-7.
24. Busquets N, Tomero E, Descalzo MA et al. Age at treatment predicts reason for discontinuation of TNF antagonists:data from the BIOBADASER 2.0 registry. Rheumatology 2011;50:1999-2004.
25. Canhao H, Faustino A, Martins F, Fonseca JE. Reuma.pt-the rheumatic diseases Portuguese register. Acta Reumatol Port 2011;36:45-56.
26. Carmona L, Descalzo MA, Ruiz-Montesinos D et al. Safety and retention rate of off-label uses of TNF antagonists in rheumatic conditions: data from the Spanish registry BIOBADASER 2.0. Rheumatology 2011;50: 85-92.
27. Carmona L, Gomez-Reino JJ. Survival of TNF antagonists in spondylarthritis is better than in rheumatoid arthritis. Data from the Spanish registry BIOBADASER. Arthritis Res Ther 2006;8:R72.
28. Chatzidionysiou K, van Vollenhoven RF. Rituximab versus anti-TNF in patients who previously failed one TNF inhibitor in an observational cohort. Scand J Rheumatol 2013;42:190-5.
29. Chen H-HMD, Chen D-YMDP, Lai K-LMD et al. Periodontitis and etanercept discontinuation risk in antitumor necrosis factor-naive rheumatoid arthritis patients:a nationwide population-based cohort study. J Clin Rheumatol 2013;19:432-8.
30. De Punder YMR, Fransen J, Kievit W et al. The prevalence of clinical remission in RA patients treated with anti-TNF:results from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry. Rheumatology 2012;51:1610-7.
31. Du Pan SM, Dehler S, Ciurea A et al. Comparison of drug retention rates and causes of drug discontinuation between anti-tumor necrosis factor agents in rheumatoid arthritis. Arthritis Rheum 2009;61:560-8.
32. Feltelius N, Fored CM, Blomqvist P et al. Results from a nationwide postmarketing cohort study of patients in Sweden treated with etanercept. Ann Rheum Dis 2005;64:246-52.
33. Filippini M, Bazzani C, Favalli EG et al. Efficacy and safety of anti-tumour necrosis factor in elderly patients with rheumatoid arthritis: an observational study. Clin Rev Allergy Immunol 2010;38:90-6.
34. Finckh A, Simard JF, Gabay C, Guerne PA. Evidence for differential acquired drug resistance to anti-tumour necrosis factor agents in rheumatoid arthritis. Ann Rheum Dis 2006;65:746-52.
35. Flendrie M, Creemers MC, Welsing PM, den Broeder AA, van Riel PL. Survival during treatment with tumour necrosis factor blocking agents in rheumatoid arthritis. Ann Rheum Dis 2003;62(Suppl 2):ii30-3.
36. Geborek P, Crnkic M, Petersson IF, Saxne T. Etanercept, infliximab, and leflunomide in established rheumatoid arthritis: clinical experience using a structured follow up programme in southern Sweden. Ann Rheum Dis 2002;61:793-8.
37. Genevay S, Finckh A, Ciurea A et al. Tolerance and effectiveness of anti-tumor necrosis factor alpha therapies in elderly patients with rheumatoid arthritis: a population-based cohort study. Arthritis Rheum 2007;57:679-85.
38. Gomez-Reino JJ, Carmona L. Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period. Arthritis Res Ther 2006;8:R29
39. Gomez-Reino JJ, Rodriguez-Lozano C, Campos-Fernandez C et al. Change in the discontinuation pattern of tumour necrosis factor antagonists in rheumatoid arthritis over 10 years: data from the Spanish registry BIOBADASER 2.0. Ann Rheum Dis 2012;71:382-5.
40. Greenberg JD, Reed G, Decktor D et al. A comparative effectiveness study of adalimumab, etanercept and infliximab in biologically naive and switched rheumatoid arthritis patients: results from the US CORRONA registry. Ann Rheum Dis 2012;71:1134-42.
41. Grijalva CG, Chung CP, Arbogast PG et al. Assessment of adherence to and persistence on disease-modifying antirheumatic drugs (DMARDs) in patients with rheumatoid arthritis. Med Care 2007;45:S66-76.
42. Gulfe A, Kristensen LE, Geborek P. Six and 12 weeks treatment response predicts continuation of tumor necrosis factor blockade in rheumatoid arthritis: an observational cohort study from southern Sweden. J Rheumatol 2009;36:517-21.
43. Heiberg MS, Koldingsnes W, Mikkelsen K et al. The comparative one-year performance of anti-tumor necrosis factor alpha drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: results from a longitudinal, observational, multicenter study. Arthritis Rheum 2008;59:234-40.
44. Hetland ML, Christensen IJ, Tarp U et al. Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry. Arthritis Rheum 2010;62:22-32.
45. Hetland ML, Lindegaard HM, Hansen A et al. Do changes in prescription practice in patients with rheumatoid arthritis treated with biological agents affect treatment response and adherence to therapy? Results from the nationwide Danish DANBIO Registry. Ann Rheum Dis 2008;67:1023-6.
46. Hishitani Y, Ogata A, Shima Y et al. Retention of tocilizumab and anti-tumour necrosis factor drugs in the treatment of rheumatoid arthritis. Scand J Rheumatol 2013;42:253-9.
47. Hyrich KL, Lunt M, Dixon WG, Watson KD, Symmons DP. Effects of switching between anti-TNF therapies on HAQ response in patients who do not respond to their first anti-TNF drug. Rheumatology 2008;47:1000-5.
48. Hyrich KL, Lunt M, Watson KD, Symmons DP, Silman AJ. Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study. Arthritis Rheum 2007;56:13-20.
49. Hyrich KL, Symmons DP, Watson KD, Silman AJ. Comparison of the response to infliximab or etanercept monotherapy with the response to cotherapy with methotrexate or another disease-modifying antirheumatic drug in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2006;54:1786-94.
50. Hyrich KL, Watson KD, Lunt M, Symmons DP. Changes in disease characteristics and response rates among patients in the United Kingdom starting anti-tumour necrosis factor therapy for rheumatoid arthritis between 2001 and 2008. Rheumatology 2011;50:117-23.
51. Hyrich KL, Watson KD, Silman AJ, Symmons DP. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Rheumatology 2006;45:1558-65.
52. Iannone F, Ferraccioli G, Gremese E, Lapadula G. Drug survival on TNF inhibitors: 2003-2004 data from Italian National Register (GISEA Register). Ann Rheum Dis 2014;73:e31.
53. Iannone F, Gremese E, Atzeni F et al. Longterm retention of tumor necrosis factor-alpha inhibitor therapy in a large Italian cohort of patients with rheumatoid arthritis from the GISEA registry: an appraisal of predictors. J Rheumatol 2012;39:1179-84.
54. Kaufmann J, Feist E, Roske AE, Schmidt WA. Monotherapy with tocilizumab or TNF-alpha inhibitors in patients with rheumatoid arthritis: efficacy, treatment satisfaction, and persistence in routine clinical practice. Clin Rheumatol 2013;32:1347-55.
55. Kievit W, Fransen J, Adang EM et al. Long-term effectiveness and safety of TNF-blocking agents in daily clinical practice: results from the Dutch Rheumatoid Arthritis Monitoring register. Rheumatology 2011;50:196-203.
56. Kievit W, Fransen J, Adang EM et al. Evaluating guidelines on continuation of anti-tumour necrosis factor treatment after 3 months: clinical effectiveness and costs of observed care and different alternative strategies. Ann Rheum Dis 2009;68:844-9.
57. Koike T, Harigai M, Inokuma S et al. Postmarketing surveillance of the safety and effectiveness of etanercept in Japan. J Rheumatol 2009;36:898-906.
58. Koike T, Harigai M, Inokuma S et al. Postmarketing surveillance of safety and effectiveness of etanercept in Japanese patients with rheumatoid arthritis. Mod Rheumatol 2011;21:343-51.
59. Koike T, Harigai M, Inokuma S et al. Safety and effectiveness of switching from infliximab to etanercept in patients with rheumatoid arthritis: results from a large Japanese postmarketing surveillance study. Rheumatol Int 2012;32:1617-24.
60. Koike T, Harigai M, Ishiguro N et al. Safety and effectiveness of adalimumab in Japanese rheumatoid arthritis patients:postmarketing surveillance report of the first 3,000 patients. Mod Rheumatol 2012;22:498-508.
61. Kristensen LE, Saxne T, Nilsson JA, Geborek P. Impact of concomitant DMARD therapy on adherence to treatment with etanercept and infliximab in rheumatoid arthritis. Results from a six-year observational study in southern Sweden. Arthritis Res Ther 2006;8:R174.
62. Mancarella L, Bobbio-Pallavicini F, Ceccarelli F et al. Good clinical response, remission, and predictors of remission in rheumatoid arthritis patients treated with tumor necrosis factor-alpha blockers: the GISEA study. J Rheumatol 2007;34:1670-3.
63. Marchesoni A, Zaccara E, Gorla R et al. TNF-alpha antagonist survival rate in a cohort of rheumatoid arthritis patients observed under conditions of standard clinical practice. Ann N Y Acad Sci 2009;1173:837-46.
64. Markenson JA, Gibofsky A, Palmer WR et al. Persistence with anti-tumor necrosis factor therapies in patients with rheumatoid arthritis: observations from the RADIUS registry. J Rheumatol 2011;38:1273-81.
65. Montag K, Gingold M, Boers A, Littlejohn G. Diseasemodifying anti-rheumatic drug usage, prescribing patterns and disease activity in rheumatoid arthritis patients in community-based practice. Intern Med J 2011;41:450-5.
66. Morgan CL, Emery P, Porter D et al. Treatment of rheumatoid arthritis with etanercept with reference to disease-modifying anti-rheumatic drugs: long-term safety and survival using prospective, observational data. Rheumatology 2014;53:186-94.
67. Neovius M, Arkema EV, Olsson H et al. Drug survival on TNF inhibitors in patients with rheumatoid arthritis comparison of adalimumab, etanercept and infliximab. Ann Rheum Dis 2015;74:354-60.
68. Oei HB, Hooker RS, Cipher DJ, Reimold A. High rates of stopping or switching biological medications in veterans with rheumatoid arthritis. Clin Exp Rheumatol 2009;27:926-34.
69. Ostergaard M, Unkerskov J, Linde L et al. Low remission rates but long drug survival in rheumatoid arthritis patients treated with infliximab or etanercept: results from the nationwide Danish DANBIO database. Scand J Rheumatol 2007;36:151-4.
70. Punzi L, Matucci Cerinic M, Cantini F et al. Treatment patterns of anti-TNF agents in Italy: an observational study. Reumatismo 2011;63:18-28.
71. Radovits BJ, Kievit W, Fransen J et al. Influence of age on the outcome of antitumour necrosis factor alpha therapy in rheumatoid arthritis. Ann Rheum Dis 2009;68:1470-3.
72. Sakai R, Tanaka M, Nanki T et al. Drug retention rates and relevant risk factors for drug discontinuation due to adverse events in rheumatoid arthritis patients receiving anticytokine therapy with different target molecules. Ann Rheum Dis 2012;71:1820-6.
73. Sarzi-Puttini P, Antivalle M, Marchesoni A et al. Efficacy and safety of anti-TNF agents in the Lombardy rheumatoid arthritis network (LORHEN). Reumatismo 2008;60:290-5.
74. Simard JF, Arkema EV, Sundstrom A et al. Ten years with biologics: to whom do data on effectiveness and safety apply? Rheumatology 2011;50:204-13.
75. Soderlin MK, Petersson IF, Geborek P. The effect of smoking on response and drug survival in rheumatoid arthritis patients treated with their first anti-TNF drug. Scand J Rheumatol 2012;41:1-9.
76. Soliman MM, Ashcroft DM, Watson KD et al. Impact of concomitant use of DMARDs on the persistence with anti-TNF therapies in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 2011;70:583-9.
77. Strangfeld A, Hierse F, Kekow J et al. Comparative effectiveness of tumour necrosis factor alpha inhibitors in combination with either methotrexate or leflunomide. Ann Rheum Dis 2009;68:1856-62.
78. Tang B, Rahman M, Waters HC, Callegari P. Treatment persistence with adalimumab, etanercept, or infliximab in combination with methotrexate and the effects on health care costs in patients with rheumatoid arthritis. Clin Ther 2008;30:1375-84.
79. Titton DC, Silveira IG, Louzada-Junior P et al. Brazilian biologic registry: BiobadaBrasil implementation process and preliminary results. Rev Bras Reumatol 2011;51:152-60.
80. Vander Cruyssen B, Durez P, Westhovens R, De Keyser F. Seven-year follow-up of infliximab therapy in rheumatoid arthritis patients with severe long-standing refractory disease:attrition rate and evolution of disease activity. Arthritis Res Ther 2010;12:R77.
81. Vander CB, Van Looy S, Wyns B et al. Four-year follow-up of infliximab therapy in rheumatoid arthritis patients with long-standing refractory disease: attrition and long-term evolution of disease activity. Arthritis Res Ther 2006;8:R112.
82. Weaver AL, Lautzenheiser RL, Schiff MH et al. Real-world effectiveness of select biologic and DMARD monotherapy and combination therapy in the treatment of rheumatoid arthritis: results from the RADIUS observational registry. Curr Med Res Opin 2006;22:185-98.
83. Yazici Y, Krasnokutsky S, Barnes JP et al. Changing patterns of tumor necrosis factor inhibitor use in 9074 patients with rheumatoid arthritis. J Rheumatol 2009;36:907-13.
84. Zink A, Listing J, Kary S et al. Treatment continuation in patients receiving biological agents or conventional DMARD therapy. Ann Rheum Dis 2005;64:1274-9.
85. Bonafede M, Watson C, Fox K et al. Tumor necrosis factor blocker treatment patterns after discontinuation within the first year of therapy initiation in rheumatoid arthritis patients in a real-world managed care setting [abstract]. Arthritis Rheum 2011;63:1547.
86. Caporali R, ScirèCA, Todoerti M et al. Drug survival of the first course of anti-TNF agents in patients with rheumatoid arthritis and spondyloarthropathies. Results from the MonitorNet database. Ann Rheum Dis 2012;71:370.
87. Chen H, Chen D, Tang C et al. Concomitant methotrexate use and the risk of drug discontinuation for adalimumab compared with etanercept in anti-TNF-naïve rheumatoid arthritis patients: a nationwide population-based cohort study [abstract]. Arthritis Rheum 2013;65:1058.
88. Cho S, Sung Y, Choi Y et al. Impact of comorbidities on TNF inhibitor persistence in rheumatoid arthritis patients:an analysis of Korean National Health Insurance claims data [abstract]. Arthritis Rheum 2011;63:2223.
89. Choquette D, Bessette L, Haraoui B et al. Combining methotrexate to etanercept does not improve its retention rate in rheumatoid arthritis patients when compared to etanercept monotherapy. A report from the Rhumadata- clinical data base and registry [abstract]. Arthritis Rheum 2013;65.
90. Choquette D, Raynauld J-P, Haraoui B, Sauvageau D. Better retention rate at 5 years of anti-TNF agents used in conjunction with methotrexate over time in patients with rheumatoid arthritis: real-life data from Rhumadata computerized database. Ann Rheum Dis 2012;71:663-4.
91. Choquette D, Sauvageau D, Bessette L et al. Comparing abatacept to adalimumab, etanercept and infliximab as first or second line agents in patients with rheumatoid arthritis: experience from the Rhumadata- clinical database and registry [abstract]. Arthritis Rheum 2013;65(Suppl 10):S186.
92. Choquette D, Sauvageau D, Haraoui B et al. Use of abatacept in patients with rheumatoid arthritis from the Rhumadata- database: experience as first or second line agent compared with adalimumab and etanercept. Ann Rheum Dis 2013;72:449.
93. Crnkic M, Petersson IF, Saxne T, Geborek P. Tolerability using survival on drug as evaluation tool. experience of etanercept and infliximab in rheumatoid arthritis (RA). Ann Rheum Dis 2002;61:793-8.
94. FafáB, Valim V, Peçanha P et al. Biological agents survival comparisons among different rheumatic disease-Brazilian register of biological agents in rheumatic diseases-BIOBADABRASIL. Ann Rheum Dis 2013;72:949.
95. Flouri I, Drosos A, Skopouli F et al. High rate of discontinuation of the first anti-TNFa agent during long term follow-up of RA patients of the Hellenic biologics registry. Ann Rheum Dis 2011;70:257.
96. Frazier-Mironer A, Cantagrel A, Combe B et al. Retention rates of adalimumab, etanercept and infliximab as first and second-line biologic therapy in patients with rheumatoid arthritis in daily practice: the MAINTAIN study. Ann Rheum Dis 2013;72:221.
97. Gibofsky A, Saunders K, Ganguli A et al. Persistency and predictors of persistency of adalimumab among rheumatoid arthritis (RA) patients in a US registry [abstract]. Arthritis Rheum 2012;64:379.
98. Greenberg J, Gibofsky A, Reed G et al. Effectiveness of TNF inhibitors (TNF-I) in biologic naïve and switched RA patients in a U.S. cohort [abstract]. Arthritis Rheum 2008;58(Suppl):S524.
99. Hanabayashi M, Kojima T, Takahashi N et al. The clinical outcome of abatacept treatment in biologic naïve patients with rheumatoid arthritis in multi-center clinical practice. Ann Rheum Dis 2013;72:620.
100. Harrold L, Reed G, Rosenblatt L et al. Comparable persistency and effectiveness of abatacept versus anti-TNF agents in the treatment of biologic-nave rheumatoid arthritis patients using the CORRONA Registry [abstract]. Arthritis Rheum 2012;62:1794.
101. Hopkins A, Martinez-Marti M, Reed GW et al. Effectiveness of TNF-áinhibitor therapy does not differ between elderly and younger patients with rheumatoid arthritis: results from the Corrona Registry [abstract]. Arthritis Rheum 2013;65:1435.
102. Iannone F, Atzeni F, Biasi D et al. Long-term survival of anti-TNF therapy in a large Italian cohort of rheumatoid arthritis patients: comparison among adalimumab, etanercept, and infliximab. Ann Rheum Dis 2011;70:255.
103. Khalil H, Tahami A. Golimumab drug utilization patterns in Canada-higher retention rate in golimumab treated rheumatoid arthritis patients compared with etanercept and adalimumab. Arthritis Rheum 2012;64(suppl):S218.
104. Kievit W, Fransen J, den Broeder AA et al. Sustained effect over 5 years of TNF blockers in daily clinical practice: results from the DREAM registry. Ann Rheum Dis 2010;69:205.
105. Kievit W, Fransen J, Kupper HH et al. The drug survival of adalimumab compared with etanercept and infliximab in treatment of patients with rheumatoid arthritis in daily clinical practice. Ann Rheum Dis 2006;65:32.
106. Kojima T, Kanayama Y, Shioura T et al. Drug survival rate for infliximab and etanercept combined with low dose MTX in Japan-results from 6 years of surveillance of clinical practice in Japanese TBC registry for the patients with rheumatoid arthritis using biologics. Ann Rheum Dis 2010;69:206.
107. Manders S, Kievit W, Jansen T et al. Significantly better results for TNFi combination therapy with MTX than TNFi mono- and combination without MTX therapy in patients with RA: results from the DREAM registry. Ann Rheum Dis 2013;72:73.
108. Navarro F, Marsal S, Gómez-Reino J et al. EULAR response and drug survival in clinical practice in RA patients treated with anti-TNF therapy: results of an observational, prospective, cohort study in Spain. Ann Rheum Dis 2006;65:333.
109. Nisell R, Stawiarz L, Lindblad S. Clinical Effect of abatacept in patients with rheumatoid arthritis, data from the Swedish rheumatology quality registry [abstract]. Arthritis Rheum 2011;63:1226.
110. Østergaard M, Unkerskov J, Krogh NS et al. Poor remission rates but long drug survival in rheumatoid arthritis patients treated with infliximab or etanercept-results from the nationwide Danish ''DANBIO'' database. Ann Rheum Dis 2005;64:59.
111. Pavelka K, Jarosova K, Chroust K et al. Efficacy of switching between TNF inhibitors for the treatment of rheumatoid arthritis in the Czech national registry of biologicals ATTRA. Ann Rheum Dis 2008;67:327.
112. Pavelka K, Zavada J, Mann H et al. Comparison of survival rates of TNFa antagonists in rheumatoid arthritis, ankylosing spondylitis, juvenile idiopathic arthritis and psoriatic arthritis in Czech national registry ATTRA. Ann Rheum Dis 2010;69(Suppl 3):525.
113. Ramiro S, Wolfe F, Harrison D et al. Comparison of discontinuation rates by biologic since 1998 in US patients with rheumatoid arthritis [abstract]. Arthritis Rheum 2012;64:495.
114. Rotar Z, Tomsic M. Survival of the second biologic after the first tumor necrosis factor alpha inhibitor's failure in the treatment of rheumatoid arthritis: prospective observational data from BioRx.si Registry [abstract]. Arthritis Rheum 2013;65:S1149-50.
115. Saevarsdottir S, Santacatterina M, Stawiarz L et al. Drug survival in patients receiving golimumab treatment 2010-2013. Results from the Swedish Rheumatology Quality Register [abstract]. Arthritis Rheum 2013;6:S641.
116. Saevarsdottir S, Stawiarz L, Turesson C, Linblad S. Previous biological therapies influence drug survival in rheumatoid arthritis patients starting abatacept treatment 2006-2012. Ann Rheum Dis 2013;72:626.
117. Sakai R, Komano Y, Nanki T et al. Comparison of drug retention rates between infliximab, etanercept, and tocilizumab and relevant risk factors for drug discontinuation due to adverse events in patients with rheumatoid arthritis. Ann Rheum Dis 2011;70:431.
118. Takahashi N, Kojima T, Kaneko A, Hirano Y, Ishiguro N. Long-term outcome of infliximab therapy in rheumatoid arthritis patients: results from Japanese Multicenter Registry System [abstract]. Arthritis Rheum 2013;65(suppl):S1013.
119. Van Vollenhoven R, Carli CC, Bratt J, Klareskog L. Sixyear report of the STURE registry for biologicals in rheumatology: satisfactory overall results, but plenty of room for improvement. Ann Rheum Dis 2006;65:511.
120. Arora A, Mahajan A, Spurden D, Boyd H, Porter D. Longterm drug survival of TNF inhibitor therapy in RA patients:a systematic review of European National Drug Registers. Int J Rheumatol 2013;2013:764518.
121. Maneiro JR, Salgado E, Gomez-Reino JJ. Immunogenicity of monoclonal antibodies against tumor necrosis factor used in chronic immune-mediated Inflammatory conditions: systematic review and metaanalysis. JAMA Intern Med 2013;173:1416-28.
122. de Vries MK, van der Horst-Bruinsma IE, Nurmohamed MT et al. Immunogenicity does not influence treatment with etanercept in patients with ankylosing spondylitis. Ann Rheum Dis 2009;68:531-5.
123. Dore RK, Mathews S, Schechtman J et al. The immunogenicity, safety, and efficacy of etanercept liquid administered once weekly in patients with rheumatoid arthritis. Clin Exp Rheumatol 2007;25:40-6.
124. Breedveld FC, Weisman MH, Kavanaugh AF et al. The PREMIER study: a multicenter, randomized, doubleblind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006;54:26-37.
125. Klareskog L, van der Heijde D, de Jager JP et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 2004;363:675-81.
126. Nam JL, Ramiro S, Gaujoux-Viala C et al. Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2013 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 2014;73:516-28.
127. Tan S, O'Mahony A, Berg E, Ganeshalingam K, Choy E. Primary human cell BioMAP- profiling of methotrexate, tocilizumab, adalimumab, and tofacitinib reveals different mechanisms of action with distinct phenotypic signatures. Arthritis Rheum 2013;65:1866.
128. Saevarsdottir S, Wallin H, Seddighzadeh M et al. Predictors of response to methotrexate in early DMARD naive rheumatoid arthritis: results from the initial openlabel phase of the SWEFOT trial. Ann Rheum Dis 2011;70:469-75.
129. Hoekstra M, van Ede AE, Haagsma CJ et al. Factors associated with toxicity, final dose, and efficacy of methotrexate in patients with rheumatoid arthritis. Ann Rheum Dis 2003;62:423-6.
130. Iannone F, Lopriore S, Bucci R et al. Two-year survival rates of anti-TNF-alpha therapy in psoriatic arthritis (PsA) patients with either polyarticular or oligoarticular PsA. Scand J Rheumatol 2015;44:192-9.
131. Ranzolin A, Brenol JC, Bredemeier M et al. Association of concomitant fibromyalgia with worse disease activity score in 28 joints, health assessment questionnaire, and short form 36 scores in patients with rheumatoid arthritis. Arthritis Rheum 2009;61:794-800.
132. Zhang J, Shan Y, Reed G et al. Thresholds in disease activity for switching biologics in rheumatoid arthritis patients: experience from a large U.S. cohort. Arthritis Care Res 2011;63:1672-9.